Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

[1]  Sung-Bae Kim,et al.  A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial , 2018, International journal of cancer.

[2]  C. Petropoulos,et al.  Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab , 2017, Oncotarget.

[3]  J. Baselga,et al.  A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer , 2017, BMC Cancer.

[4]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[5]  Veeraraghavan,et al.  HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer , 2017, Clinical Cancer Research.

[6]  A. Abdou,et al.  Human Epidermal Growth Factor Receptor-3 mRNA Expression as a Prognostic Marker for Invasive Duct Carcinoma not Otherwise Specified. , 2017, Journal of clinical and diagnostic research : JCDR.

[7]  F. Cardoso,et al.  The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review , 2015, Breast Cancer Research.

[8]  N. Kanomata,et al.  Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab , 2015, Breast Cancer.

[9]  B. Bossenmaier,et al.  Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody , 2015, Cancer Chemotherapy and Pharmacology.

[10]  R. Nahta,et al.  Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach? , 2015, Cancer.

[11]  M. Gnant,et al.  Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. , 2014, Breast.

[12]  W. Han,et al.  Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. , 2014, Anticancer research.

[13]  E. Lerma,et al.  Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma , 2014, British Journal of Cancer.

[14]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[15]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Sliwkowski,et al.  Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy , 2013, Clinical Cancer Research.

[17]  Violeta Serra,et al.  Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. , 2008, Cancer research.

[18]  G. Mills,et al.  Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .

[19]  J. Baselga,et al.  Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. , 2007, Journal of the National Cancer Institute.

[20]  V. Blanc,et al.  Direct Detection of Herceptin/Trastuzumab Binding on Breast Tissue Sections , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[22]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[23]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[24]  J. Koland,et al.  Mutation of a Shc Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-dependent Activation of Mitogen-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.

[25]  N. Hellyer,et al.  ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. , 1998, The Biochemical journal.

[26]  A. Lenferink,et al.  The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin , 1998, Oncogene.

[27]  P. Fedi,et al.  Epidermal growth factor and betacellulin mediate signal transduction through co‐expressed ErbB2 and ErbB3 receptors , 1997, The EMBO journal.

[28]  J. Weber,et al.  Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases , 1997, Nature.

[29]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[30]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[31]  W. Gullick,et al.  Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.

[32]  L. Cantley,et al.  The erbB3 gene product is a receptor for heregulin. , 1994, The Journal of biological chemistry.

[33]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[34]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.